Skip to main content
. Author manuscript; available in PMC: 2019 Jul 15.
Published in final edited form as: Clin Cancer Res. 2018 Apr 10;24(14):3433–3446. doi: 10.1158/1078-0432.CCR-17-2793

Figure 4. GR chromatin association is altered by concomitant treatment with a GR antagonist.

Figure 4.

(A) Genome-wide GR peaks and associated genes annotated to TSSs +/− 100kB of these peaks; (B) GR chromatin association with transcription factor response elements (REs) following Dex and GR antagonist treatment reveals significant changes in GR enrichment at GREs, AP1 and ELK REs compared with Dex alone (CentriMO); (C) GR chromatin association in proximal promoter regions (0–3kb from the TSS) is diminished following Dex/Mif or Dex/C297 treatment while more distal GR peak association is proportionally increased.